SEC Form 4 · accession 0000899866-19-000025
ALEXION PHARMACEUTICALS, INC. · ALXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Bazarko
Officer — SVP, Controller, CAO
Period of report
Feb 27, 2019
Accepted (ET)
Mar 1, 2019 · 4:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000899866
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $.0001 per shareF1 | Feb 27, 2019 | F | 70 | $135.58 | D | 4,737 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units.